IMNN announces 2026 R&D Day highlighting Phase 3 OVATION 3
IMUNON says it will host a 2026 R&D Day featuring Phase 3 OVATION 3 and the clinical potential of IMNN-001.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
IMUNON says it will host a 2026 R&D Day featuring Phase 3 OVATION 3 and the clinical potential of IMNN-001.